SCHEDULE: Orca Capital AG Discloses 4.3% Stake in Rani Therapeutics Holdings, Inc.

Orca Capital AG has filed an amended Schedule 13G, reporting a 4.3% beneficial ownership stake in Rani Therapeutics Holdings, Inc.'s Class A Common Stock.

Summary

• Orca Capital AG, a German entity, has reported beneficial ownership of 1,891,623 shares of Rani Therapeutics Holdings, Inc.'s Class A Common Stock.
• This ownership represents 4.3% of the total Class A Common Stock outstanding, which is calculated based on 43,606,522 shares.
• Orca Capital AG holds sole voting power and sole dispositive power over all 1,891,623 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported ownership position.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of institutional ownership in a publicly traded company within the biotechnology or pharmaceutical sector, common for investment firms holding significant, but non-controlling, stakes.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.

Key Dates

Keywords

Rani Therapeutics Holdings Inc., Orca Capital AG, Schedule 13G, Beneficial Ownership, Class A Common Stock, SEC Filing, Institutional Ownership